POXEL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.67 EUR | -0.89% |
|
+1.67% | +21.60% |
| Apr. 11 | Poxel: CDC falls below the 10% threshold | CF |
| Feb. 15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Presentation Operator MessageOperator (Operator)Ladies and gentlemen, welcome to the Poxel's c...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
2024-05-15
- Q1 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +21.60% | 28.34M | |
| +7.52% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.58% | 16.81B | |
| +37.41% | 12.54B | |
| -23.95% | 8.09B |
- Stock Market
- Equities
- POXEL Stock
- News Poxel
- Transcript : Poxel SA, 2017 Earnings Call, Mar 22, 2018
